Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Oxford Biodynamics PLC (OBD)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
8.99 -0.30    -3.23%
16:35:59 - Closed. Currency in GBP ( Disclaimer )
  • Volume: 714,817
  • Bid/Ask: 8.30 / 9.20
  • Day's Range: 8.82 - 9.00
Type:  Equity
Market:  United Kingdom
ISIN:  GB00BD5H8572 
SEDOL:  BD5H857
Oxford Biodynamics 8.99 -0.30 -3.23%

OBD Interactive Chart

 
Our live advanced Oxford Biodynamics PLC share price chart is interactive, allowing you to interact with the 2024 OBD data that is relevant to you.

You have the option to change the appearance of the interactive Oxford Biodynamics PLC stock charts by varying the time scale, chart type, zooming in to different sections and adding new studies or indicators such as RSI, MACD, EMA, Bollinger Bands, Fibonacci retracements and many more.

You can save your Oxford Biodynamics stock studies and create your own systems as well as having the option to set the colours of each object on the chart by logging into your free investing account.
Sign In / Free Sign Up now to save your chart settings.
press ESC to exit fullscreen mode
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

OBD Price Commentary

Write your thoughts about Oxford Biodynamics PLC
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Jeff King
Jeff King Sep 29, 2023 11:33
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Continues to rise in price fabulous products.
Reply
1 0
Report
Gareth Barnes
Gareth Barnes Sep 27, 2023 8:04
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Copied from another site:-What's the true value of thisToday 08:00It's always difficult to get a true market value, but if we look at what we know Analysts at Shore Capital said: “There are approximately 47 million men in the relevant 50-80 age range in the key US market and 25 million PSA tests per year, and a further 10 million men in the UK. The medical need for an improved test is clear. I saw a video posted on here where the company stated the product would cost around £100 each. 57,000,000 x £100 = 5.7 billion. Divide that by the share issue you're looking at £41 a share. Admittedly this is a very simple and quite frankly overly optimistic analysis, but it gives us some indication
Reply
3 0
Report
Jeff King
Jeff King Sep 27, 2023 8:04
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
The potential for this stock is fantastic
Reply
2 0
Report
Gareth Barnes
Gareth Barnes Sep 27, 2023 8:04
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
RE: Prostate cancer test market should be in 2023 approx 8.5B USDToday 10:30OBD has previously highlighted its extensive pipeline of deployable molecular tests, in several disease areas, indicating that the most likely prospects for subsequent product development are in prostate and colorectal cancer screening, and canine lymphoma. This remains the case and we have been proceeding with internal and collaborative R&D work in these areas. In prostate cancer, for example, OBD is involved in a Prostate Cancer Research-funded project to develop a test to aid detection of prostate cancer in black men, who suffer both increased prevalence of, and mortality from, this disease compared to other groups. This work, carried out in conjunction with University of East Anglia (UEA) and Imperial College NHS Healthcare Trust builds on OBD's successful participation in the PROSTAGRAM trial. A forthcoming paper jointly written by OBD with Department of Surgery and Cancer, Imperial College, London; S
Reply
2 0
Report
Gareth Barnes
Gareth Barnes Sep 26, 2023 15:51
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Thats is some diagnostic test. World beater and blockbuster!!
Reply
4 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email